This trial is evaluating whether Oral Methamphetamine will improve 1 primary outcome and 3 secondary outcomes in patients with HIV Infections. Measurement will happen over the course of 4 hours.
This trial requires 10 total participants across 2 different treatment groups
This trial involves 2 different treatments. Oral Methamphetamine is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
HIV infections are the infection that causes AIDS. This infection can also cause other diseases like Hepatocellular Carcinoma. This can happen just when HIV infection is present or gone. The patient should be monitored and treated here.
Risk factors include poor sanitation, unprotected sexual behavior, and multiple sex partners. To prevent the spread of HIV, the World Health Organization's global strategy is to prevent transmission by reducing partners' risk by providing antiretroviral treatment and counseling. Furthermore, education campaigns are essential to raise awareness of the preventive strategies. It is important to recognize the social dimensions of HIV/AIDS because of the consequences of the disease, such as stigmatization of the carriers and of the people living with the disease.
Early signs of HIV infections include genital pain and bleeding in the genital region of the female patient or hiv positive male patients. When the hiv positive person has unprotected sex with a partner infected with HIV then a partner getting an STD is also a risk factor for HIV infection.
Very rarely an AIDS patient with an early illness could be successfully treated and cured of the virus from pre-existing opportunistic infection prior to antiretroviral therapy. However, very early and aggressive medical treatment is necessary to prevent development of the virus.
About 1.5 million new sexually acquired infections (STDs) (mainly chancroid, syphilis, and HIV) occur each year. The number of newly infected persons with STDs may be as high as 2 to 3 million annually. Most of the new STDs, although uncommon in older adults (age 50 to 59), are common among younger adolescents (age 15 to 19). In 2005, 1.5 million new STD cases occurred in persons under 19 years of age.
It is evident that a range of medications are used to treat hiv infections. HIV can be treated with a combination of antiretrovirals (ARVs, including protease inhibitors), nucleoside reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The choice of ARV depends on the patient's viral load and the drug's potency and side effects. However, no consistent pattern exists and patients may need other medications in conjunction or as an alternate to their initial drug regimen.
This analysis indicates that the use of oral methamphetamine is a significant factor in the perceived health status of HIV+ people that is not adequately addressed by currently available treatment guidelines. This highlights the importance of more research into the use of methamphetamine by those living with hiv.
In our study, hiv-discordant couples had a low likelihood of receiving clinical trial treatment compared with noninfected, single, and mixed-serodiscordant couples, even after adjusting for other risk factors. Recent findings support the notion of [considering HIV status when selecting clinical trials for HIV-positive patients for the purpose of providing evidence-based medicine in resource-limited settings] (www.science-behavior.
Methamphetamine appears to be safe, if used in a carefully considered way by people with a clinical history and a full medical and mental health history.
Findings from a recent study show that new oral therapies currently researched will improve the pharmacokinetics, pharmacodynamics, and tolerability of oral M. The new oral M drugs may increase the drug bioavailability and reduce its first pass metabolism. The drugs will be more convenient for use (i.e., shorter period of time for administration, lesser requirement for compliance, better overall compliance for the patients). M-oral drugs are likely to be prescribed less frequently for the treatment of stimulant dependence and for a broader range of indications as compared with current treatments for stimulant abuse.
Current knowledge suggests that meth (primarily orally) can be addictive and increase relapse in subjects with a history of addiction. The high rate of relapse is alarming and highlights the need for more rigorous research investigating other routes of administration, the optimal dose, and the pharmacokinetics and metabolic effects of oral meth. In addition, the effects of meth in other drug-using populations are intriguing and need to be studied further.
While new drugs continue to be developed, there has been a lack of new discoveries regarding drugs to treat human immunodeficiency virus infections. Current drug candidates focused on combating HIV are aimed at a very specific target of the virus, the HIV envelope protein gp120.